Evolus EOLS 深 滬
已收盤 05-08 16:00:00 美东时间
6.36
-0.030
-0.47%
華盛通- 最 高6.58
- 今 開6.33
- 成交量 84.49万股
- 最 低 6.32
- 昨 收 6.39
- 總市值 4.19亿
- 52周最高 10.62
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.86
- 委 比 94.00%
- 總股本 6585.48万
- 歷史最高 39.50
- 量 比 0.47
- 振 幅 4.07%
- 歷史最低 2.85
- 每 手 1
- 風險率 1.85%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Evolus shares are trading higher after the company reported better-than-expected Q1 sales results.
Evolus shares are trading higher after the company reported better-than-expecte...
05-05 23:02
Evolus Earnings Call Highlights Profitable Growth Path
Evolus, Inc. (($EOLS)) has held its Q1 earnings call. Read on for the main high...
05-05 08:26
Evolus Ends ATM Facility After Strong Q1 Momentum
Evolus ( ($EOLS) ) has shared an update. Evolus terminated its unused at‑the‑ma...
05-05 04:55
Evolus Affirms FY2026 Sales Guidance of $327.000M-$337.000M vs $330.020M Est
Evolus (NASDAQ:EOLS) affirms FY2026 sales outlook from $327.000 million-$337.000 million to $327.000 million-$337.000 million vs $330.020 million estimate.
05-05 04:11
Evolus Q1 Adj. EPS $(0.16) Misses $(0.13) Estimate, Sales $73.137M Beat $72.288M Estimate
Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 6.67 percent decrease over losses of $(0.15) per share from the same
05-05 04:10
Earnings Scheduled For May 4, 2026
Companies Reporting Before The Bell • Pulse Biosciences (NASDAQ:PLSE) is likely...
05-04 19:11
Why eBay Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
eBay (NASDAQ: EBAY) rose sharply after GameStop (NYSE: GME) proposed to acquire it for $125/share, valuing GME at $55.5B. eBay shares jumped 8.1% to $112.50 in pre-market trading.
05-04 16:57
AEON Biopharma Sets Annual Shareholder Meeting
AEON Biopharma announced its 2026 annual shareholder meeting on June 17 at 10:00 am PT in Irvine, CA, with meeting materials to be available by April 29. The company disclosed a going concern audit qualification due to liquidity, expecting cash to last into Q3 2026. AEON focuses on ABP-450, a BOTOX biosimilar, targeting U.S. market entry.
04-24 20:05
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
AEON Biopharma received a notice from NYSE American indicating non-compliance with additional listing standards due to a stockholders' deficit of $55 million and losses in three of its four most recent fiscal years. The company must regain compliance by August 3, 2026, to avoid delisting proceedings. AEON continues to execute its approved plan to meet listing requirements while maintaining its business operations and stock trading under the symbo...
04-03 20:05
Telix Appoints David Gill as Non-Executive Director
<p>Telix Pharmaceuticals Limited has appointed David Gill as a Non-Executive Director, effective May 11, 2026, with plans for him to become Chair in the future. Mr. Gill, a seasoned executive with over 35 years of experience in finance and leadership roles, brings expertise in capital markets, business scaling, and corporate strategy. Telix, a global biopharmaceutical company focused on radiopharmaceuticals, aims to strengthen its board as it con...
04-01 23:53
